1	UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY		
2			
3	PATRICIA O'CONNOR and : MEGAN O'CONNOR, :	Case No. 2:16-cv-05177-JLL-JAD	
4	: Plaintiffs, :		
5	:	Newark, New Jersey	
6	:	Wednesday, August 8, 2018 12:02 p.m.	
7	et al.	12.02 p.m.	
8	Defendants.		
9	TRANSCRIPT OF STATUS CONFERENCE BEFORE THE HONORABLE JOSEPH A. DICKSON		
10	UNITED STATES MAGISTRATE JUDGE		
11	APPEARANCES:		
12		w Office of Eric J. Warner, LLC: ERIC J. WARNER, ESQUIRE	
13	23	3 Mount Airy Road, 1st Floor sking Ridge, NJ 07920	
14		Sking Klage, No 07920	
15	For Defendant The Dodge Company, Inc.: McGivney, Kluger & Cook, P.C.		
16	Ву	By: EMILY R. WEISSLITZ, ESQUIRE 23 Columbia Turnpike, 3rd Floor	
17		orham Park, NJ 07932	
18			
19			
20		J Transcription Service, LLC O. Box 8627	
21	Sa	ddle Brook, NJ 07663 one: (201)703-1670	
22	ww	w.kljtranscription.com fo@kljtranscription.com	
23		rogrijeranscriperon.com	
24	Proceedings recorded by electronic sound recording, transcript		
25	produced by transcription service.		

2 1 APPEARANCES (Cont.) 2 For Defendant Pierce Chemicals Royal Bond Co.: Hallett & Perrin, P.C. 3 By: LELAND C. DE LA GARZA, ESQUIRE 1445 Ross Avenue, Suite 2400 4 Dallas, TX 75202 5 Michelman & Robinson, LLP By: BROOKE K. HALEY, ESQUIRE 6 800 Third Avenue, 24th Floor New York, NY 10022 7 For Defendant Hydrol 8 Chemical Company, Inc.: Harris Beach, PLLC By: DAVID J. DINO, ESQUIRE 9 100 Wall Street New York, NY 10005 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

		3	
1		<u>INDEX</u>	
2			
3	COLL	COLLOQUY ON DISCOVERY DISPUTES: PAGE	
4	Re:	Extension of Discovery Deadlines 4, 68	
5	Re:	Objection to Scope/Breadth "Any and All" 6, 29	
6	Re:	Material Safety Data Sheets	
7	Re:	Warning Labels	
8	Re:	Marketing Materials	
9	Re:	Formulas	
10	Re:	Testing & Inspection	
11	Re:	Processes Used	
12	Re:	Law Governing Chain of Distribution 55, 60	
13	Re:	Complaints on Products	
14	Re:	Litigation Files	
15	Re:	Alternative/Foreseeable Uses of Products67	
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			

4 Colloquy 1 (Conference commenced at 12:02 p.m.) 2 THE COURT: All right. We're on the record on 3 O'Connor versus Dodge, Docket Number 16-5177. 4 May I have appearances, please? 5 MR. WARNER: Good, I believe it's afternoon at this 6 point, Your Honor. Eric J. Warner here from the Law Office of 7 Eric J. Warner, LLC, co-counsel for the O'Connors. 8 THE COURT: Okay. 9 MR. DE LA GARZA: Your Honor, I'm Leland de la Garza 10 and I'm with Hallett and Perrin, and I'm counsel with Brooke 11 Haley. 12 THE COURT: Okay. 13 MS. WEISSLITZ: Good afternoon, Your Honor. Emily 14 Weisslitz of McGivney Kluger and Cook on behalf of defendant, 15 The Dodge Company. 16 THE COURT: Okay. 17 MR. DINO: Good afternoon. David Dino from Harris 18 Beach on behalf of defendant Hydrol. 19 THE COURT: Okay. So, this is a discovery dispute 20 here. And have you been able to resolve anything since I got 21 papers in on this? 22 MR. DE LA GARZA: No, Your Honor. 23 MR. WARNER: Well, I -- Your Honor, certainly I have 24 been speaking with Ms. Weisslitz' firm, McGivney and Kluger 25 and Cook. She represents The Dodge Company. She asked for

Colloguy 5

six additional weeks for document production and we have no issue with that.

We -- we -- my -- my client is do -- her health is very poor. It's unlikely, but we may have to do a *de bene* esse deposition. She now has some sort of necrosis as a resultant -- a result in some -- from the treatment that she received. I only found this out yesterday, so the medical term -- I don't have the -- what the medical terminology necessarily memorized just yet, but my client is not doing very well and so I -- however, we -- if we a -- have another four weeks that we can amass what Your Honor can imagine are the voluminous medical records stemming not only from (indiscernible) but also now from this additional illness, we -- we'd appreciate it.

So, that kind -- but otherwise, I think -- I think
Ms. Weisslitz and I agreed on that with respect to her need
for six weeks and my need for at least four weeks to gather
together, you know, medical records and see how my client's
health progresses.

THE COURT: All right. So, let me make sure I understand what's going on. You're still gathering medical records --

MR. WARNER: Yes, Your Honor.

THE COURT: -- and you want an additional four weeks. From what, I don't know. I don't remember what all

6 Colloquy 1 our dates are, but whatever. 2 And you're looking for six weeks from now? 3 MS. WEISSLITZ: From today, yeah. 4 THE COURT: To complete your document production? 5 MS. WEISSLITZ: Yes. Your Honor, --6 THE COURT: And you're ask -- just so I understand 7 something, because we were talking about this. Plaintiffs' 8 first set of document demands to all named defendants, that's 9 what you're responding to? 10 MS. WEISSLITZ: Correct. 11 THE COURT: So, you're not really part of the fight 12 today. 13 MS. WEISSLITZ: Correct. 14 THE COURT: Okay. And you just need six more weeks? 15 MS. WEISSLITZ: Yeah. It's my client -- I think 16 everyone will concede that my client is the heavy in this case. There's almost 40 products that have been identified by 17 18 plaintiff that were manufactured by my client and plaintiff is 19 asking for materials that date back to the early '90s, so it's 20 just a matter of getting all of these materials, so my client 21 just needs a little bit more time to get those materials 22 together. 23 We have not lodged the same objections that my co-24 defendants have lodged. We just need additional time, plus my 25 client, they recently switched over to a new Website, so for

7 Colloquy 1 the materials that plaintiff is quest -- requesting relative 2 to pictures of the product bottles and warning labels, we just 3 need additional time to get those to plaintiff. 4 THE COURT: Well, that raises an interesting 5 proposition in my mind. If the heavy -- using your words --6 MS. WEISSLITZ: Yeah. 7 THE COURT: -- is going to produce the documents 8 that you're objecting to from her client, what does that do to 9 your objections? First of all, will these documents -- and this may be a question for you -- obviate the need to get the 10 11 same documents or similar type documents from the other co-12 defendants? 13 MR. WARNER: Well, no, Your Honor. They all 14 manufacture different products. It -- you know, it's -- it would be like saying that, you know, documents from Ford will 15 16 suffice for Chevy. 17 THE COURT: Well, because I was under the 18 understanding that -- well, this is the problem I'm having. 19 MR. WARNER: Okay. THE COURT: Because you had one document demand to 20 21 all the defendants. 22 MR. WARNER: Mm-hmm. 23 THE COURT: For instance, Ms. Haley -- is that who I'm talking to? 24 25 MS. HALEY: I am Ms. Haley, yes.

8 Colloquy 1 THE COURT: Yeah, I know who you are, but I mean who 2 -- one of the two of you from Pierce Chemicals, --3 MS. HALEY: (Indiscernible) 4 THE COURT: -- are the -- are there 30 identified 5 products, chemicals? 6 MR. WARNER: So -- right. So, in -- I -- the exact 7 number in the complaint, I can't -- I can't give a precise --8 that sounds right, though, Your Honor. 9 THE COURT: All right. For purposes of today's 10 argument, let's say 40. 11 MR. WARNER: That sounds right. 12 THE COURT: Yeah, but not -- not -- if there are 38, 13 then I am not adding to them. If there are 47, I'm not taking 14 away. But we're -- for purposes of today's argument, there 15 are 40. You asked for the information on all 40 from all of 16 the defendants; right? 17 MR. WARNER: Well, yes, because, for example, the 18 heavy has I'd say 30 chemicals and -- or 30 products and the --19 and the rest -- the other three have -- I believe one or two 20 of them only have three or four products. But, you know, 21 basically, we -- basically, Your Honor, what we need to know 22 is do they contain formaldehyde, were there warnings about 23 formaldehyde, when did the manufacturers first learn about the 24 hazards of formaldehyde, did they put any mark -- did they put 25 any warnings about formaldehyde in their marketing materials.

9 Colloquy 1 See, these are all manufacturer, distributor, independent --2 THE COURT: Well, did they object to those -- I 3 don't think they objected to those. 4 MR. WARNER: I thought they did. 5 MR. DE LA GARZA: Your Honor, I am representing 6 Pierce, along with Ms. Haley. 7 And so the complaint against Pierce is that Pierce 8 has one product, Powertone --9 THE COURT: Right, I see that. 10 MR. DE LA GARZA: -- (36 Index) --11 THE COURT: And my clerk is reminding me. 12 MR. DE LA GARZA: Okay. So, for -- as we understand 13 it, the only complaint against Pierce is that one product, yet 14 one of the reasons that we're objecting to the discovery is 15 that Pierce does manufacture other products, not products that 16 plaintiff has alleged caused this leukemia. And so, for 17 documents related to all those other products, then we're 18 objecting, --19 THE COURT: All right. MR. DE LA GARZA: -- because it has nothing to do 20 21 with the case. 22 THE COURT: Are you looking for products that are 23 not identified in your complaint? 24 MR. WARNER: Well, --25 THE COURT: For inform -- for discovery on products?

10 Colloquy 1 Is it the same for --2 MR. DINO: Yes, for --3 THE COURT: -- your client is also one; right? 4 MR. DINO: For Hydrol we have one. We're in the 5 same position as --6 THE COURT: Right. Okay. 7 MR. WARNER: Well, we respectfully, Your Honor, so 8 it's the -- so far -- as far as we can tell from our initial 9 pleading, it looks like there has been they only have one 10 product each, but we're -- we're reluctant to take our 11 adversaries' word for that all products that -- that we know 12 my client used during her career, that none of other -- none 13 of the other ones that we've identified contain formaldehyde 14 or none of the other ones that -- you know, for example, my 15 recollection of the jurisdictional discovery deposition was 16 that, I mean, in some instances she used -- and I could be 17 wrong and I'm sure I'll be corrected -- but that she used 18 Hydrol products and Pierce products, some of them which may be 19 not have been specifically identified. We're -- we're just a 20 little reluctant to accept our adversaries' word for it --21 THE COURT: Well, how do we identify those products? 22 She worked for -- who did she work for? 23 MR. WARNER: So, she worked for -- it was a funeral 24 home --25 THE COURT: It's not a defendant here today.

```
11
                               Colloquy
1
              MR. WARNER: I'm sorry?
2
              THE COURT: It's --
3
              MR. WARNER: Yeah. Correct. It would -- right.
4
    Because of workers' compensation.
5
              THE COURT: And they basically gave her the products
6
    to use in her job.
7
              MR. WARNER: Yes. Yes, Your Honor.
8
              THE COURT: So, to identify what products she
9
    touched, do you have to go through the defendant -- not the
10
    defendant -- the employer's records?
11
              MR. WARNER: No, --
12
              THE COURT: Isn't that how we find -- isn't that how
    we discover them?
13
14
              MR. WARNER: We -- it -- we -- correct, Your Honor.
15
    We -- we -- we have -- and, of course, --
16
              THE COURT: And if their records don't reflect
17
    anything other than the one product you've identified from
18
    Pierce and Hydrol, then tell me why I should allow you to get
    information on all the other myriad of products that they
19
20
    manufacturer, which we have --
21
              MR. WARNER: I --
22
              THE COURT: -- we have no indication were in this
23
    case.
24
              MR. WARNER: Well, Your Honor, I just -- I don't see
25
    any harm if -- if they -- if they do manufacture other
```

12 Colloquy 1 formaldehyde-containing products, I don't see any harm why 2 sending how their --3 THE COURT: Well, it could be -- because you've 4 asked for 9 -- going back to 1990. 5 MR. WARNER: Exactly. Right. 6 THE COURT: That's a lot of information. 7 MR. WARNER: At -- at -- well, at this rate, I'm --8 I'm -- I'm sure that if -- if they -- if there are, you know, 9 material safety data sheets that say that certain chemicals 10 and certain products do contain formaldehyde, we -- we'd like 11 to -- we'd simply like to know about it. 12 THE COURT: Well, why? Because they may have --13 they -- I'm not saying they did, but they may have 14 manufactured 100 products that contained formaldehyde, none of 15 which found their way to your client's employer or your 16 client. MR. WARNER: Well, I -- for -- that's true, Your 17 18 Honor, and I think -- I think that -- I think the basis behind 19 this is what we don't believe they did. I think that they --20 they manufactured -- and -- and -- and, again, I'll be 21 corrected if I'm wrong -- it wouldn't -- it wouldn't have been 22 100 product -- different products, but -- you know, I -- I --23 I think that -- you know and generally, though -- and, of 24 course records going back to the '90s with -- were written 25 records and everything to that effect and there may --

seat for a minute.

Colloquy 13

THE COURT: That's going to be a lot of work.

Depending on -- let's -- let me give -- take you off the hot

Mr. de la Garza, how many product -- do we know how many products containing formaldehyde your client manufactured going back to 1990?

MR. DE LA GARZA: Well, our product -- our client manufactured a bunch of products. I can't tell you 30, 40, but many products that contained formaldehyde, because formaldehyde is a primary ingredient of embalming-related products. So, you have different embalming products for different uses.

And so this one particular one that is at issue with regard to Pierce is the one that was alleged to have been used by this plaintiff. You kind of have to go back to the original complaint. The original complaint wasn't all that clear about the products. And so we filed the motion to dismiss. The Court granted the motion to dismiss, ordered repleading, there was repleading, and so now you have a complaint that is very specific about what comp -- what products were used.

For example, on page 7 of the complaint, the amended complaint, beginning at paragraph 22, there is a discussion of the specific product. So we went from maybe some broader ill-defined products to the specific product that was used.

Colloquy 14

So now, the way this case is framed, the plaintiff has pled which specific products were used, not just against Pierce, but against the other defendants, as well. For example, with regard to Dodge, in paragraph 7 there's a long list of the products that it -- that are alleged to have been purchased by the plaintiff's employer and which she used, and those are the products that are at issue.

So now we have a complaint that frames it very specifically, so the issue that I think each of these defendants has is when you asked for us to produce a lot of documents related to other products that you haven't raised as being used and causing the leukemia and you're -- now you're delving into something that is not relevant and it -- the -- you know, it's not proportional to the needs of this case. That's why we are objecting to that portion.

THE COURT: I understand.

Mr. Warner, I tend to agree.

MR. WARNER: Oh, look, I -- I -- you know, I think -I think probably where this -- you know, I think where -where we went into the weeds here, too, is that we were
fighting over the language "any and all." As long as we -- I
-- I -- if they don't want to give us information
regarding products that we have not yet been able to identify
that she has used, I -- I don't think that that's terribly,
again, going to be the end of the world for us.

Colloquy 15

Basically, however, but with respect to the products that we have identified that she has used -- and I just rereviewed my notes here. I think that was probably the main -- the primary issue here was that we would like to have documents regarding those products. And since the non-heavies here have -- I -- and I believe they've represented they only have one product each -- you know, as long as they can produce all -- any and all documents regarding those, we -- we have to know about the material safety data sheets, we know -- need to know about warning labels, we need to know about advertising materials, we need to know when they first learned about formaldehyde as -- as hazardous.

So -- and -- and that -- and that's fair. I mean, that -- I -- you know, I -- I think that I don't see any reason why we wouldn't be able to obtain that.

THE COURT: And do you object to providing those types of materials with respect to the one product that has been identified for your client?

MR. DE LA GARZA: No, Your Honor. For example, we -we've always maintained that the material data safety sheets
are the best way for the plaintiff and their counsel to know
what was in these products, because it discloses that, as
required by federal law. And counsel was referring to any and
all documents, you know, if -- in the beginning, when we
conferred, we did have a conference and tried to talk to these

1 issues and we had a discussion about both sides using the

2 beginning of their request saying "any and all documents

3 referring to." All right? So, we kind of got past that,

because we --

all" is not an issue.

THE COURT: Okay.

MR. DE LA GARZA: -- we both did it. A good point. So, if we're both doing it, we're not going to be complaining about it. And so that's not an issue. That whole "any and

What's an issue is, for example -- and I would break this down into three categories. And our letter lays it out in three categories.

First, there is a request for documents that relate to conditions or products not in dispute. So, products not in dispute, we've been talking about that. And so for conditions not in dispute. Well, the condition here is she says that she contracted cancer, specifically leukemia, as a result of the use of the product.

So, for example, if there is a request for documents related to conditions other than that -- for example, skin irritations, there could be other conditions that might be caused by using these products -- that we shouldn't have to produce documents related to that, because that's not what's at issue.

What the plaintiff is trying to prove is that the

17 Colloquy 1 formaldehyde in the defendants' products caused her to suffer 2 from leukemia. That's the only claim at issue. And so, as we've identified them in our letter -- on page 2 of our 3 4 letter, we've identified specific document requests 1, 2, 3 5 for Pierce. For Hydrol it would be 21 and 32. And that's on 6 page 2 of our letter to the Court. 7 THE COURT: Mm-hmm. 8 MR. DE LA GARZA: And so we're saying with respect 9 to those we shouldn't have to answer for irrelevant product 10 defects or irrelevant defective conditions or irrelevant 11 illnesses, because that's not what's raised by the pleadings. 12 We have another category which is --13 THE COURT: Okay. Let me -- let's stop there for a 14 minute. 15 MR. DE LA GARZA: Okay. 16 THE COURT: The products we've kind of dealt with. 17 I'm saying that I agree with you. And unless I'm just missing 18 your point right now, you mean products other than the one 19 identified. 20 MR. DE LA GARZA: Correct. 21 THE COURT: And I agree with that and you've --22 MR. WARNER: I -- I -- I --23 THE COURT: And you're ready to give that up without 24 prejudice for now. 25 MR. WARNER: Without prej -- well, Your Honor, but I

18 Colloquy think what my adversary is saying, too, he feels that even for 1 2 this single product, if there's a skin irritation --THE COURT: No, no, I know. I'm going to get there 3 4 That's -now. 5 MR. WARNER: And -- and --6 THE COURT: I got that. So, what do you -- what do 7 you say to that? 8 MR. WARNER: I mean, I -- you know, I -- I -- I do --9 we -- I -- I think that it's possible that, you know, -- and, 10 of course, you never want to say it's possible in a federal 11 courtroom, but nevertheless, what we're talking about is over 12 decades here where we didn't have data -- data keeping as well 13 as we do now. 14 For -- for -- let me start it this way. Material 15 safety data sheets, the -- the -- the law -- the lit -- the 16 item -- the documents that tell you exactly the hazards of the 17 chemicals, how to use them, what to wear, they have changed 18 significant -- they change about two years, as far as I could 19 They -- they -- they've changed constantly. So, I -- I 20 mean, basically, we're looking for all those material safety 21 data sheets and, you know, a lot of those material safety data 22 sheets --23 For example, let's say one -- let's say one product 24 may have a material safety data sheet that says, you know, 25 formaldehyde, that it contains formaldehyde, known to cause

```
19
                               Colloquy
1
    cancer to humans, those are in or about 1993. I think that
2
    was when the FDA first started to recognize -- or -- or at
3
    least that's when the FDA start -- first started to recognize
4
    that it caused cancer in -- in lab rats. But then, you know,
5
    another -- a similar material safety data sheet that for a
6
    formaldehyde product from around that time may not have that
7
    information in that and I think that would be useful
8
    information.
9
              I just I don't -- I don't see the harm necessarily
    in being -- providing the -- these documents for all
10
11
    formaldehyde-containing products. That's --
12
              THE COURT: I'm just -- you lost me slightly. I
13
    thought --
14
             MR. WARNER: Okay. Sure, sure, sure.
15
              THE COURT: I want to make sure I say this correctly.
16
    Data material or material data? What --
17
             MR. WARNER: The material safety data sheets.
18
              THE COURT: Material safety data sheets.
19
             MR. WARNER: Correct, correct.
20
              THE COURT: He's -- he wants to give you those;
21
    correct?
22
              MR. DE LA GARZA: Correct.
23
              THE COURT: And that's good.
24
             MR. WARNER: Yeah.
25
              THE COURT: So, what else do you need aside from
```

```
20
                               Colloquy
1
    those --
2
              MR. WARNER: Sure. Well, okay, but --
3
              THE COURT: -- to -- there's -- there's another
4
    issue which you didn't quite address and that's hooking up --
5
    let's use the general term skin rash that -- that perhaps the
6
    product they -- perhaps they have data as to whether their
7
    product causes or could cause skin rash. Are you looking for
8
    that and why wouldn't that be in the material data safety
9
    sheet?
10
              MR. WARNER: Okay. Well, certainly, it would be --
11
              THE COURT: Material safety data sheet.
12
              MR. WARNER: That -- that -- that is the type of
    information --
13
14
              MS. HALEY: MSDS is usually how --
15
              MR. WARNER: Right. That --
16
              MS. HALEY:
                         -- they refer to is.
17
              THE COURT:
                         Say that again?
18
              MS. HALEY: MSDS.
19
              MR. WARNER: Right.
                                  That -- that is the type of
20
    information that would be in a material safety data sheet.
21
    Leukemia --
22
              THE COURT: So if you get that, you should have what
23
    you're looking for.
24
              MR. WARNER: Well, yes and no. So -- so --
25
              THE COURT: Well, let me hear -- just let me -- let
```

```
21
                              Colloquy
1
   me -- it's yes and the no is maybe the old ones didn't have
2
    everything. Right?
3
             MR. WARNER: Boy, I -- may I -- I think I -- may --
4
   may I --
5
             THE COURT: Sure, sure.
6
             MR. WARNER: -- may I -- let me -- let me
7
    try and frame this.
8
             THE COURT: Okay.
9
             MR. WARNER: Leukemia has a lot of symptoms. Right?
10
   Like right now, for example, my client has necrosis. We're
11
   not even -- we just found out yesterday. We're not even sure
12
    where it is. Some sort of necrosis, some sort of tissue
13
    disorder. Her -- her skin -- her -- or it's either her skin
14
    or part of her body is dying. Cells are just dying.
15
             Leukemia is a disease of many symptoms. If, for
16
    example, one says skin rash, well, and it said that in 1990,
17
    you know, or if it said that in 2000, but it didn't say
18
    leukemia, we might want to know that.
19
             Warning labels, too. You know, maybe one --
20
             THE COURT: Wait, wait. Stop with the -- don't do
21
    the warning labels.
22
             MR. WARNER: Okay. Okay. Sure, sure, sure.
23
             THE COURT: I want to stick with this and tell me
24
    why the --
25
             MR. WARNER: Sure.
                                 Mm-hmm.
```

22 Colloquy 1 THE COURT: -- MSDS are not enough to let you 2 understand what the other symptoms might be. I mean, you're 3 going to have to have a doctor look at this, too. 4 MR. WARNER: Of course. Of course. 5 THE COURT: So, isn't this a place to start? 6 MR. WARNER: What, is -- is Your Honor suggesting 7 that we only would receive the MSDSes from -- from adverse 8 counsel and --9 THE COURT: Well, what's the next category of 10 documents that you want? 11 MR. WARNER: Warning labels on the products where --12 where the end user can see --13 THE COURT: Why shouldn't they get warning labels? 14 MR. DE LA GARZA: Your Honor, can I ask a question? 15 Just for clarification. Is counsel talking about the MSDSes 16 for all products or just the one in --17 THE COURT: We're talking about the one product. 18 MR. DE LA GARZA: Okay. Because I had thought that 19 he had ventured onto all products. 20 THE COURT: No, we're not going to all products. 21 We're talking about the one product. 22 MR. WARNER: Well, a warning label is the heart of 23 any --24 THE COURT: No, no, no. MSDS. One product. 25 Warning labels -- well, why not warning labels?

23 Colloquy 1 MR. DE LA GARZA: Pierce has no problem with 2 producing, to the extent that we have them, warning labels 3 that were on the products. So, all we're talking about is a 4 label that's slapped on the -- the plastic container. I am 5 not speaking for other --6 MR. DINO: Same for Hydrol. 7 MR. DE LA GARZA: -- defense counsel. 8 THE COURT: Okay. 9 MR. WARNER: And oftentimes it's actually just 10 printed right on the bottle, but yeah, but warning labels, for 11 example, --12 THE COURT: Okay. So, warning label. What's the 13 next category of documents you want? 14 MR. WARNER: Sure. Marketing materials. For 15 example, they -- within -- you know, for -- I believe it was 16 in --17 THE COURT: Marketing -- let's go to marketing 18 materials. 19 MR. DE LA GARZA: There is no issue in this case 20 that turns on the marketing materials. So, if we produce the 21 material safety data sheets, we're showing what's in the 22 product. We produce to you warning labels, we're produce --23 we're showing you what we've disclosed to the user could be 24 the risk associated with using this product. 25 So, marketing materials is a broad request for

Colloquy 24

documents that extends to how that product is marketed in different states and -- and also, I believe this would be request number 3. Request number 3 is for relating to all defective conditions that existed or you thought exists in any of your embalming products.

Now, we've already got past the "any," so we're just talking about all defective conditions. The problem with the marketing materials simply is the way that it's been requested is over broad and then also there is simply no cause of action that turns on those marketing materials.

MR. WARNER: Well, Your Honor, so at her deposition my client did testify that there were catalogs that she reviewed that were kept at the funeral home, that she believed there was a whole drawer of them. You know, gee whiz, maybe if one of the catalogs had said warning formaldehyde, she wouldn't -- she wouldn't -- have gotten cancer.

THE COURT: Well, the way you're -- okay. The -- and I understand the argument. And the way you're arguing -- let's -- when I back and read number 3 and then I hear counsel's argument and I hear what you're saying, I do think that there's room here for you to narrow the request. If you ask for catalogs, I'd likely -- I think they'll produce those.

MR. WARNER: Well, and -- and the other --

THE COURT: Either with my encouragement or not.

MR. WARNER: And -- and, Your Honor, may -- may I?

25 Colloquy 1 This -- this is -- this is, like, a big industry. These -these -- these people --2 3 THE COURT: But here's my problem. 4 MR. WARNER: Okay. 5 THE COURT: And I don't mean to -- I don't want 6 anybody to get nervous that I said the word "problem." 7 I think we need a little more meet and confer. I 8 understand you did meet and confer and I under -- because you 9 told me you did, but you need to narrow that down. 10 So, I don't want to sit here for the next 20 minutes 11 and go through everything you would want under 3. Catalogs, I 12 think is an easy one. But I want you to go back and think about it and talk to counsel. 13 14 And I actually see another reason why some of these 15 marketing materials -- he hasn't articulated it here yet, but 16 I am not going to do his job for him and I may be even wrong, 17 so -- so, I'm not -- that's why -- but I think there are some 18 marketing materials that might be relevant to this case under 19 the what we have left in the -- pled in the case. 20 But I do agree that this is very, very broad, so we need to go back to that one. All right? 21 MR. WARNER: Okay. 22 23 THE COURT: And work a little bit. 24 MR. WARNER: Okay. And I -- respectfully, I -- and 25 I'm -- I'm not very optimistic about meet and confer.

26 Colloquy if -- if Your Honor will recall, the last telephone conference 1 2 Your Honor asked for --3 THE COURT: I assume -- well, you need to be more 4 positive about meet and confers. That's number one. 5 Number two. Four attorneys here doing their jobs. 6 They just heard what I said. I don't think they're going to 7 call me back in two weeks and say they've agreed to nothing 8 but catalogs. I think there's probably other types of 9 documents, but you need to specify which ones and why. I 10 mean, any and all defective conditions, again, you've kind of 11 put that to the side for a minute. 12 MR. WARNER: Okay. 13 THE COURT: We're talking about this disease. The 14 MSDSes I think is a really great -- I don't know how many 15 there are going to be and how -- you know, I don't think 16 that's a lot; right? You've got one product and you have one 17 per year. Or do they come out more than once a year? 18 MR. DE LA GARZA: They're not one per year, but we 19 would have multiple iterations. 20 THE COURT: But how many? 21 MR. DE LA GARZA: I -- I don't know, Your Honor. 22 THE COURT: A hundred? 23 MR. DE LA GARZA: Oh, no, no, no. 24 MS. WEISSLITZ: No, it's every two to five years. 25 THE COURT: Yeah, so that's -- it's not -- this is

```
27
                               Colloquy
1
    not a burden.
2
              MR. WARNER: Well, --
              THE COURT: So, let's start there at least.
3
4
              MR. WARNER: And --
5
              THE COURT: Catalogs I agree with. But I don't want
6
    to get involved in every little piece of document.
7
              MR. WARNER: Of course.
8
              THE COURT: That's not my job to do that.
9
              MR. WARNER: I -- I -- I understand and I just -- I
10
    just wanted to add that, you know, manufacturers will -- will
11
    -- will issue different MSDSes for Canada and the EU and it
12
    would be interesting to see if, for example, in the EU they're
    saying, oh, it contains formaldehyde, but in the U.S. they
13
14
    don't. So, I mean, that's the -- but we'll -- we'll -- I
15
    quess we'll meet and confer and hopefully we'll come to a
16
    resolution soon.
17
              THE COURT: Well, I just found out my heart -- blood
18
    pressure medication, depending in who manufactures it,
19
    contains something that will kill me.
20
              MR. WARNER: I hear that, too, Your Honor. It's --
21
    I wasn't -- I wasn't -- I was -- I don't -- I take a different
    one. I take Benicar and that's not --
22
23
              THE COURT: It turned out that I'm okay. Thank you
24
    very much.
25
              MR. WARNER: Yes.
```

Colloquy 28

MR. DE LA GARZA: Your Honor, we actually did have a conference, but not with this counsel. We had it with Mr. Tandy. And when we had that conference with Mr. Tandy, it was pretty short, because Mr. Tandy basically said he wasn't going to change his position. He said he would send us a letter laying out his position with regards to our discovery and we haven't gotten that. So, we have another discovery dispute that's brewing, but, you know, we're -- we're trying to follow the orders of the Court, which is don't bring a problem to you until we've met and conferred.

THE COURT: I understand.

MR. DE LA GARZA: And so we haven't finished that process yet, but, you know, all of our side dedicated time to have the phone conference with Mr. Tandy. If we now have a conference with this counsel and/or Mr. Tandy, you know, especially guided by your instructions to confer, it probably is going to productive.

THE COURT: And -- well, and always remember, meet and confer, we should -- if I get a chance to write an opinion on this that hopefully changes the rule somewhere, it should say meet and compromise. Okay?

And there are no -- there's always -- I've been on the job for eight years here and there is always room for compromise. I -- maybe there's -- maybe there's those one or two cases where somebody has been completely unreasonable, but

Colloguy 29

1 generally there's room for compromise.

All right. So, what is the next --

MR. WARNER: Well, I mean, I -- I think the only other next thing is that I think that my adversary -- well, for example, was Pierce -- one -- one of my adversaries -- the one complaining about "any and all" uses "any and all" in their own documents, so I guess --

THE COURT: I thought you worked that out, though.

MR. WARNER: I'm -- we're going to work it out?

THE COURT: I thought he said it was worked it.

MR. WARNER: Well, I -- I didn't -- I thought he --

MR. DE LA GARZA: The way it got worked out was, once counsel, Mr. Tandy, pointed out that some of our requests said any and all, then we no longer objected to that. So, when we sent a letter to Mr. Tandy laying out what our issues with his discovery were, we raised that with him. But when we sent a letter to the Court laying out what our issues are, we didn't raise that issue. When we responded with our responses and objections, we did not make those objections. And because our view was, you're right, if we used the words "any and all" in this discovery and you used the words, we don't have a

The next go around, maybe we would be more careful with how we actually do our discovery. That's just not an issue here.

basis for complaining about it.

Colloquy 30

So, the next issue really is, in our -- in our second grouping, that the plaintiff is seeking access to our formula for our product. Marketing materials, you know, we need -- we kind of already talked about that. We're going to have to discuss that further. Testing, inspection results, some sort of very broadly defined sales materials. So now you have marketing and sales, probably we'll talk about that.

So, I think what we're really talking about is they want -- they want our formula for the product. They want inspections and testing results. And not necessarily constrained to whether or not, for example, if you tested the product and it showed that it can cause cancer. Or you inspected the product and if -- and it was too much, therefore it would cause cancer. So, we'll start with that.

Start with the formula. I mean, that one right there, you don't need the formula in order to now that the product has formaldehyde. Nobody contests that the products that are at issue have formaldehyde. Am I speaking out of turn?

MS. WEISSLITZ: No.

MR. DINO: No.

MR. DE LA GARZA: And so, if we don't contest that and the plaintiff has alleged that, and their claim is it's a simple syllogy, it can -- it's your product, it contains formaldehyde, and I had access and used it and I got sick.

1 And that's the syllogy.

So -- and -- and so -- and they don't need the formula to know, for example, if we put particular dyes into it in order to make the skin look rosier. They don't need that information.

MR. WARNER: Your Honor, that's -- in re -- with respect to my counsel, it's a bit of a silly syllogy, because what I've learned is that there is synergy usually between these chemicals. So, for example, we flew in a toxicologist from Berkeley last time -- the last time we had a case like this and oftentimes formaldehyde, the -- the toxin -- toxic effect of it may increase when it's combined with another substance. Not being a toxicologist and not knowing the formula, we just don't know.

But so I -- I just (indiscernible chuckling while speaking) alliterations (indiscernible) you know, for -- as far as the syllogy goes, there's a synergy that has to be considered. And I think that, you know, if our toxicologist examines it, I think -- I think we'll be -- but -- but, you know, as far as -- as far as anything as a trade secret or something, I don't see where there couldn't be a confidentiality or something to that effect.

MR. DE LA GARZA: That's not a claim that's been alleged, that there has been any aggravation by other ingredients. The allegation is it contains formaldehyde,

1 formaldehyde makes you get cancer, and that's it.

2 MR. WARNER: Well, --

THE COURT: I understand, but there -- I am not shocked --

Can we -- can you do me a favor? Can you push that microphone down it's, like, right between your eyes and my eyes. Thank you.

I am not -- I don't think it constitutes a fishing expedition to know the -- to know the formula so that their toxicologist can ultimate -- so that their toxicologist can be in a position one way or the other to determine whether the product that you sold to his client's employer was dangerous because it contained formaldehyde mixed with X.

That's the -- I understand that's not a specific allegation in the complaint, because I think probably because he could never make that allegation, because they don't have the formula and they only know it's formaldehyde. So, --

MS. WEISSLITZ: Your Honor, if I may?

The MSDSes, as well as the labels, they contain all the chemicals in the products. The specific formula relative to the percentages, I would argue that that's proprietary and I would argue that plaintiffs' expert, through the document production, has everything they need to make the analysis that plaintiff is requesting.

THE COURT: Well, then maybe this is --

1 MR. WARNER: But --

THE COURT: Let's -- if your expert -- if you come back and make an argument that I find persuasive that you need the percentages, based on science that your expert will tell us why you need the percentages, then maybe I'll reconsider that. But why isn't that good enough?

MR. WARNER: Well, for example, so may -- maybe if they're willing to stip -- well, our last -- our last formaldehyde client smoked for -- for 20 or 30 years and everyone was -- everyone's hair was on fire, oh my god, he smoked for 20 or 30 years, there's a synergistic effect. It turns out that there are studies that if he had only smoked for ten years it wouldn't have been that bad of a deal, but now, since he smoked for 20 years, well -- well, you know, you -- you can forget about -- you know, that's comparative negligence right there.

So, percentages do matter. I mean, I -- you know, I was -- I've been down -- you know, I've done enough of these toxicolo -- tox -- toxic tort --

THE COURT: What you're saying sounds logical to me, but I don't think I have enough in front of me -- well, let's back up for a minute.

What harm -- what actual prejudice would you suffer by turning over the formula, assuming we have a discovery confidentiality order and it's -- and, you know, whoever can

view that formula, it's restricted to that and there's all kinds of protections, as we normally have in federal court?

And we have them in patent cases and we have them in antitrust cases, we have them in class actions, so I'm sure that we can have one here. So, how are you prejudiced by turning over the

MR. DE LA GARZA: Your Honor, if you were to provide all of the protection that you just said, then you probably have ameliorated almost all of those risks. You know, we wouldn't want, for example, to -- to be able to have our defense counsel see our formula and they wouldn't want us to see their formula.

THE COURT: Yeah, I -- I thought about that. That's the problem we have to deal with.

MR. DE LA GARZA: But I --

formula?

THE COURT: Because you're not going to be able to use their formu -- it's going to -- this could get very tricky and very dangerous -- but, I'm sorry, I interrupted you. Go ahead.

MR. DE LA GARZA: No, well, that -- that's the point, really, and -- and I think you were onto the right track, which is before we get into what is a sticky area, let's see if we need to be in a sticky area. Is there any proven reason why we need to get into this sticky area?

So, I would suggest to the Court that where you were

1 headed is the right way to go, which is we produce our 2 material data safety sheets, that tells you what the 3 ingredients are, he has an expert. If his expert can make a 4 showing which he presents to the Court for why that's actually 5 necessary, then the Court can entertain that request at that 6 Then we can deal with all these complicated issues 7 between us. 8 THE COURT: It's conceivable -- I'm not saying 9 probable, I am not saying likely, it's conceivable that your 10 toxicologist is going to look at the ingredients and say it 11 doesn't -- none of these, under any science I know, have any 12 effect of making it worse. 13 MR. WARNER: Have we even established that these are 14 trade secrets? Are they? Are they? 15 THE COURT: I'm sure they're trade -- I --16 MR. DE LA GARZA: It's not publicly disclosed 17 information what --18 THE COURT: If each one of these defendants --19 MR. DE LA GARZA: -- percentages there are --20 THE COURT: -- has a different formula for their 21 embalming products, I think that's a trade secret. But if you 22 really want to contest that, you are within -- I'll put the 23 burden on them to tell me why it's a trade secret and then 24 I'll -- but we're not there yet. 25 MR. WARNER: Okay.

36 Colloquy 1 THE COURT: We're not there. I think this is the 2 way to go. Have your tox -- I assume you already have a 3 toxicologist. 4 MR. WARNER: Yes, and --5 THE COURT: Have your toxicologist look at the 6 MSDSes and -- and if he -- and you make an argument to me -- I 7 mean, first of all, you're going to talk to them. 8 But there is an issue, and I've faced it in this 9 court before, now we have attorneys' eyes only, but I think 10 you mean scientists. Maybe I'm wrong. 11 MR. WARNER: And we'll pay him another couple grand 12 to look at them and look at it again -- look at it again, I 13 quess. THE COURT: Well, I don't know if you've got to pay 14 15 him a couple of grand. I mean, it sounds like this -- it's a 16 one page sheet or is it 50 page document? 17 MR. WARNER: Well -- well, if you go from -- from 18 1990 when for she -- when she first started working and if we 19 are allowed to get the ones from Canada and the EU, as well, I 20 mean, we're -- we're talking about a lot of stuff, especially 21 with Dodge. 22 THE COURT: Well, they're going to produce it, so 23 you've got to review it, so I'm not --24 MR. WARNER: Well, our toxicologist is going to be 25 the one that's going to be looking at. I mean, that's --

37 Colloquy 1 THE COURT: But now -- I understand, but -- but this 2 is a -- this is the case you chose. 3 MR. WARNER: Yeah, of course. 4 THE COURT: So, you have to --5 MR. WARNER: I -- I just --6 THE COURT: -- you have to go through it. 7 Now, so, where are we? 8 MR. DE LA GARZA: So, we have talked about formula, 9 Your Honor. The next related are -- requests are they're 10 requesting documents that refer to the processes involved in 11 the production of the products, the tests that anyone 12 performed on the products, not limited to any particular kind of test, particular purpose, and documents referring to any 13 inspections anybody ever performed on the products not related 14 15 necessarily to this particular condition that's at issue, --16 THE COURT: You're going to narrow all that down; 17 right? 18 MR. WARNER: Well, Your Honor, I mean, I think 19 testing of these products -- it goes toward when they first 20 learned formaldehyde was --21 THE COURT: Oh, I think I am going to give you 22 inspections and testing results, but the question is which 23 testing and which inspections. You're talking about anything 24 that's got the word -- and I'm being simplistic here, I'm not 25 locking you into this -- but we're talking about things that

Case 2:16-cv-05177-ES-JAD Document 97 Filed 08/10/18 Page 38 of 74 PageID: 2974 38 Colloquy 1 result in cancer or leukemia. 2 MR. WARNER: I -- I -- Your Honor, I -- I thought 3 that was implied, but I guess it's not, so that's why we're 4 here. I thought for -- I -- with respect, I thought it was 5 implied. I mean, it -- if they wanted to answer under 6 objection saying over broad, we're not going to give you stuff 7 that's a test about the air quality and the -- and, you know, 8 or -- well, that might actually be (indiscernible) -- but a 9 test about the acidity level or something or -- you know, then 10 that's fine, then -- then at least we can do that, but I -- I 11 mean, I thought this was implied. 12 THE COURT: All right. Well, apparently it wasn't, 13 so --14 MR. WARNER: I -- I don't see --15 MR. DE LA GARZA: Well, the --16 THE COURT: Do you still object once we've narrowed 17 it down? 18 MR. DE LA GARZA: Well, what I would -- I would say 19 we have to figure out how to narrow that down in order to make

that relevant. So, for example, my client -- when I talked to my client about, well, what kind of testing or inspection might you do?

THE COURT: Mm-hmm.

20

21

22

23

24

25

MR. DE LA GARZA: And it's a chemical production process.

39 Colloquy 1 THE COURT: Mm-hmm. 2 MR. DE LA GARZA: So, the ultimate test is when you 3 get it out at, you know, at the end of the, in effect, the assembly line, then you look at what you've got to see if it 4 5 has the right percentages, in terms of --6 THE COURT: Does it work? 7 MR. DE LA GARZA: -- of the chemicals. And then 8 does it have the right look, does it have the right smell. 9 Whatever all those things are that they're testing. 10 what they're doing. Those are more of the appearances, the 11 composition, as opposed to something that would relate to --12 THE COURT: The efficacy of the product. 13 MR. DE LA GARZA: Yeah. 14 MR. WARNER: And -- and if they're to --15 MR. DE LA GARZA: As opposed to the whether or not --16 THE COURT: Whether it causes cancer. 17 MR. DE LA GARZA: -- it would cause cancer. So, if 18 you were to say, --19 THE COURT: Well, --20 MR. DE LA GARZA: -- you know, a test for the color, 21 nothing to do with this lawsuit. 22 THE COURT: Yeah, but how burdensome -- I don't --23 you haven't told me, I don't think, how burdensome it is. I 24 don't know how many -- the way you just described it sounds

logical to me, that they have a quality assurance guy come in

40 Colloquy 1 at some -- maybe every day, maybe once a month, maybe every 2 run, I don't know, but whatever they do they do and -- and 3 they test it and then they put the test results in the file. 4 Right? 5 MR. DE LA GARZA: Right. 6 THE COURT: And maybe it only tests for color, 7 smell, degree of formaldehyde, whatever. And it -- but it 8 says nothing about disease causing, because that's not what 9 they're testing it for. 10 MR. DE LA GARZA: Correct. THE COURT: Okay. First of all, just so that 11 12 counsel has done his job and we don't have a problem later on, 13 why would you not produce at least a sampling of those to show 14 this is what we do on a regular basis? And maybe do one from 15 every decade or something. Or --16 MR. DE LA GARZA: I wouldn't have a problem with 17 producing a sample of a test so that counsel could see what 18 are we testing. 19 THE COURT: And --20 MR. DE LA GARZA: And I don't speak for all of the 21 defendants, but that -- that is --22 THE COURT: But we also want to make sure, --23 MR. DE LA GARZA: -- more -- less burdensome. 24 THE COURT: -- because we're talking about a long --25 talking about a long period and we want to make sure that

```
41
                               Colloquy
1
    whenever the type of testing changed, you're getting a sample
2
    of the new test.
3
              MR. DE LA GARZA: Right.
4
              MR. WARNER: So -- oh, I'm sorry.
5
              THE COURT: Just let me finish.
6
              MR. WARNER: Forgive me. Forgive me. I'm sorry.
7
              THE COURT: Okay. So, that's -- it's more of a take
8
    it out of the case thing than it is giving them ammunition.
9
              MR. DE LA GARZA: So, what I think we're talking
10
    about is an example of a test during the time period defined
11
    by the lawsuit, and to the extent that the test changed, then
12
    an example of the next test.
13
              THE COURT: Right.
14
              MR. DE LA GARZA: If the format changed or the
15
    actual test changed, --
16
              THE COURT: Mm-hmm.
17
             MR. DE LA GARZA: -- then we give them an example of
18
    that one. So, example for -- of each test that would have
19
    been performed, each inspection that would have been
20
    performed.
21
              THE COURT: Yes.
22
              MR. DE LA GARZA: So he could decide do I want more.
23
              THE COURT: Exactly. I'm not --
24
              MR. DE LA GARZA: Fair?
25
              THE COURT: -- foreclosing your right to say this is
```

42 Colloquy 1 going to take us down a path to now right to the heart of the 2 lawsuit. 3 MR. WARNER: And -- and I -- and I -- and that's 4 fair, Your Honor, and I -- I -- I would only say if -- if the 5 discovery had been responded to under the objection, then we --6 we probably wouldn't even be here right now saying that, you 7 know, --8 THE COURT: All right. Well, you're here. 9 MR. WARNER: But -- but that -- but that -- but, you 10 know, actually, though color and smell, you know, sometimes 11 she didn't take her (indiscernible), sometimes it was already 12 in the machine, and it could have been a certain shade of red 13 and that's how she may have identified a certain product. 14 mean, you know, so stuff -- stuff -- stuff like that is 15 certainly relevant, as well, but --16 THE COURT: All right. I'm not say --17 MR. WARNER: -- you know, --18 THE COURT: -- but you're going to get that under 19 any -- you're going to get that. 20 What's the next area? And by the way, you said 21 something that we didn't addressed. You talked about 22 processes. And I don't know why that's relevant, so I'm going 23 to say no to the processes. Until you tell me why you need to 24 know exactly how they make their product. You're going to

know what is in their product, you're going to know what

43 Colloquy 1 testing -- they performed on the product. You're going to get 2 certain marketing materials on the product. You're going to 3 get the catalogs. I don't know why the processes are 4 relevant. 5 MR. WARNER: Well, the -- well, let's -- let's say 6 did their workman's comp insurance come in and say these 7 people are working with formaldehyde, make them wear the --8 make them wear the cartridge respirators. That goes to 9 process. 10 THE COURT: Well, yeah, but that's totally 11 different. I don't know enough about this, but speculating, 12 raw formaldehyde here, product over here. I could see why a quy handling it over here might need more than your client 13 14 over here. 15 MR. WARNER: Well, I mean, I think that if you -- if 16 you have a plant that has a vat of raw formaldehyde that's 17 being poured into other substances, then that -- then I --18 THE COURT: That may very well be dangerous, --19 MR. WARNER: I -- I -- I --20 THE COURT: -- but that's not your case. 21 MR. WARNER: Well, exactly, but if we knew, for 22 example, that, you know, this -- that -- that one defendant 23 had -- required all of its employees to don a cartridge vest --24 respirator before going to the assembly line, well, then we 25 would say, well, heck, why the heck didn't it say in your

```
44
                               Colloquy
1
    material safety data sheet that they should have done that,
2
    too?
3
              THE COURT: Because it might be totally different at
    the other end of the assembly line. I don't --
4
5
              MR. WARNER: Well, you're -- I think what Your Honor
6
    is saying, that an embalming room might be different than an
7
    assembly line may in a --
8
              THE COURT: Yeah.
9
              MR. WARNER: -- in a factory.
10
              THE COURT: Yeah.
11
              MR. WARNER: Well, that may be so, but we're --
12
    we're never going to know though unless we know what the
13
    process is.
14
              THE COURT: Well, you can think about this one and --
15
    and I understand where you're going. Right now, I am not
16
    seeing it. You've got to give me a little bit more on the
17
    connection between protecting the worker in the factory
18
    handling raw -- I'm assuming raw formaldehyde, whatever that
19
    means; I'm just making that up -- with an embalming product
20
    that they have a responsibility to make sure can be used
21
    safety under FDA reg -- is it FDA?
22
              MR. WARNER: F -- it's everything, Your Honor.
23
    EPA, FDA, all -- it -- I mean, it --
24
              THE COURT: Under government supervision.
25
              MR. WARNER: Well, so -- so that's why we -- we
```

45 Colloquy 1 would need to know the -- the parts per million in the factory 2 and then the -- we can compare it with the parts per million 3 in the embalming room. 4 THE COURT: I -- but only if you're going to -- if 5 you're representing a worker who has come down with cancer in 6 the factory. 7 MR. WARNER: Yes, but except for the -- well, let's 8 say the parts per million is equal or even less than the parts 9 per million in the -- in the embalming room and everyone on 10 the assembly line has a cartridge respirator, but nothing in 11 the warning label or the MSDS says you've better put on a 12 cartridge respirator. I think a jury would -- should hear 13 that. 14 THE COURT: We're going to say no for now. I need 15 more information after you've gotten everything that you've 16 got. 17 MR. WARNER: Can I at least have the parts per 18 million at least in the factory? Because I think that would 19 at least --THE COURT: Can you have what? I'm sorry? 20 21 MR. WARNER: Can I have the parts per million in the 22 factory that -- because, I mean, these are things that we've 23 been asking for and they all -- they all sort of meld 24 together. They -- they -- they're all -- I --THE COURT: Why can't you give him the parts per 25

46 Colloquy 1 million in the factory --2 MR. WARNER: I --3 THE COURT: -- or whatever that means? I --MR. WARNER: Well, parts per million in the -- in 4 5 the air. 6 THE COURT: I know what you mean. I didn't mean 7 what you mean. I wasn't --8 MR. WARNER: Having the --9 THE COURT: I wasn't trying to be snotty about the 10 way you said it, I'm just -- it hasn't been scientifically 11 defined to me yet. 12 MR. DE LA GARZA: I think counsel is creating a 13 scenario, in order to defend his request, that doesn't exist. 14 There is no measurement in the factory of parts per million, for example, in the air. That's just not being measured. 15 16 And I am going to make an assumption here that there 17 is some sort of respirator or there's some sort of clothing 18 and all that that's used in the factory. And I do agree with 19 the -- the proposition that what happens in the factory is not 20 the same setting as what happens over in the embalming room. 21 You're using one small container of the fluid, as opposed to 22 maybe being standing next to a vat of the same stuff. 23 And so, unless some scientist says that there is 24 some direct correlation between the experience of the worker 25 in the factory and the experience of the embalmer, I don't see

47 Colloquy how -- how that could ever be relevant, could -- and could 1 2 ever turn into anything relevant. 3 THE COURT: Yeah, where -- you're trying to make 4 this case too big. This is a case about what happened to your 5 client after being exposed to these products over a period of 6 time and that's -- and that's what's in this case. But to try 7 to go back and find out how dangerous it may or may not have 8 been in the factory and what precautions they took in the 9 factory is -- is I think relevant in a very esoteric sense of 10 the word. 11 MR. WARNER: May -- may -- may I just respond? 12 THE COURT: Yep. 13 MR. WARNER: To my adversary? 14 So, it -- it's not just one bottle, you're actually 15 taking the blood out of somebody, which is a lot, and putting 16 it -- and replacing it with fluid and it's -- it's a -- a 17 factory presumably is a much -- is a large facility with open 18 air, whereas an embalming room -- and we've all visited them --19 is -- is probably the size of Your Honor's chambers. 20 So, I -- I -- again, I would --21 THE COURT: So, they're not the same. 22 MR. WARNER: Well, they're not -- well, very, very 23 few things are exactly the same in our line of work, Your 24 Honor, respectfully, but I -- I just think that I -- I think

this was a request that we succeeded on in state court, simply

48 Colloquy 1 because if -- you know, if -- if what's good for the goose is 2 good for the gander. If -- if you -- if you -- if you're trying to avoid workers' comp suits, because you want your 3 4 worker being -- you know, you -- you don't want to get sued, 5 you know, you -- you don't want -- you want to make sure your 6 worker -- there's worker safety and O -- when OSHA slips by, 7 you don't get fined, and -- and there's nothing in your MSDSes 8 that says otherwise, then I -- I -- I think what's good for 9 the goose is good for the gander. 10 MR. DE LA GARZA: I don't even really --11 THE COURT: Give me one second. Please. 12 MR. DE LA GARZA: -- know how to respond to that. 13 THE COURT: Give me one second. 14 (Extended pause) 15 THE COURT: All right. Go ahead. MR. DE LA GARZA: Well, I was simply saying, Your 16 17 Honor, I don't really understand what counsel was just saying. 18 I don't really understand his argument. I think that we've 19 already made the point these are totally disparate situations. 20 There's -- there's just simply no relevance to it. 21 Counsel keeps on making references to the MSDSes and 22 they should make disclosure that you need protective 23 equipment. Well, the reality is they do. That's not being 24 raised here. And, you know, at some point we'll probably have

the proper setting to show you all the MSDSes, to show you the

49 Colloquy 1 labels. And we also don't have the benefit of presenting to 2 you the testimony of Patricia O'Connor with regard to the fact 3 that she did use protective equipment and protective clothing. 4 So, you know, we're -- I think we're getting way 5 ahead of ourselves in discovery. 6 THE COURT: I don't think you briefed this issue. 7 MR. WARNER: Well, --8 THE COURT: And that's why I stopped for a minute, 9 to go back and look at your letter. 10 MR. WARNER: I -- I -- I think -- I think what --11 what -- in our -- well, first -- first of all, the protective 12 equipment changed dramatically since 1990 when Patricia 13 O'Connor started working. 14 In our -- in our letter, Mr. Tandy -- you know, I'm 15 not -- I'm not jumping on him, but he -- I -- I -- and I --16 actually, he and I both worked on it. Basically, what we're 17 saying is process is process. Process is -- or, you know, 18 maybe we should have said process -- maybe we could have been 19 more specific, but, frankly, I mean, you know, we just -- we 20 just figured that, you know, these are -- these are defendants 21 that represent sophisticated enough clients as to certain --22 certainly -- certainly these things should simply just be 23 implied. 24 I mean, I -- I -- I don't -- not -- very 25 rarely is anything in our profession the same. We're lucking

50 Colloquy if it's similar. And in this case, if we have -- if we have a 1 2 factory owner who goes, oh my god, what if OSHA comes by and 3 I'm not -- I'm -- and I'm -- you know, and I'm -- and I'm --4 I'm done -- I'm done with, or if my own -- my -- my workers' 5 comp insurer stops by, I'm done with, I mean, everyone better 6 put on your -- your -- your respirators, you know, and -- and 7 -- and it --8 And, again, this changed dramatically over the past 9 several decades. When Patricia O'Connor started, I think they 10 were lucky if they -- if they wore surgical masks. And -- and 11 these are things I learned from toxicologist in my last suit. 12 It's -- it's --13 THE COURT: Well, that -- it -- you know, that's 14 going to depend on whether or what the state of the art and 15 the knowledge was at the time. 16 MR. WARNER: Well, and how are we going to know that 17 though unless, you know, we know what their process --18 THE COURT: Well, you're going to get everything to 19 tell you what it was for that. You're arguing now that you --20 that they have to open up their factory floor to you --21 MR. WARNER: Well, --22 THE COURT: -- and I --23 MR. WARNER: I have no desire to go there, I mean, --24 THE COURT: No. All I'm saying is right now I am

not seeing that relevance, nor do I think that -- and I want

```
51
                               Colloquy
1
    you to understand what I am saying here. I am not shutting
2
    this down forever and for all time.
3
              MR. WARNER: Uh-huh.
4
              THE COURT: I am not denying it with prejudice.
5
             MR. WARNER: Sure.
6
              THE COURT: But I am denying it today and I -- and
7
    that's why I went back and looked at your letter. I don't
8
    think you've really argued this why you need to go that far
9
    that way.
10
              MR. WARNER: I -- I just -- and well, I -- I suppose
    I don't think we -- we expected this much resistance. Again,
11
12
    I -- I mean, you know, these are -- these -- you know, Ms.
13
    Weisslitz knows, she's represented a lot of the toxic
14
    companies, and I -- I -- we -- we --
15
              THE COURT: And this is something you always get?
16
              MR. WARNER: -- we -- we --
17
              THE COURT: You always get the --
18
              MR. WARNER: No.
19
              THE COURT: -- the processes and the manufacturing?
20
             MR. WARNER: We got it last time, yeah. I mean, I --
21
    if my recollection serves me correctly, I think we got
22
    everything from OSHA, we got OSHA testing, we got -- I mean,
23
    good lord, we got quality air sampling in the company, oh,
24
    they've -- you know, they've -- they were sure to do that.
25
    Because qual -- and I -- again, if we want to wait for
```

```
52
                               Colloquy
1
    toxicologist, that's fine, but nowadays --
2
              THE COURT: How did you get it from OSHA?
3
              MR. WARNER: I'm sorry?
4
              THE COURT: Did you -- how did you -- last time,
5
    wherever that was, how did you get it from OSHA?
6
              MR. WARNER: I don't think even it was a motion or
7
    anything, was it?
8
              THE COURT: No. Did you subpoena it from OSHA or
9
    did you get it from --
10
              MR. WARNER: Oh, oh, it was -- it was --
11
              THE COURT: -- your defendants in --
12
             MR. WARNER: -- it was a FOIA. It was a FOIA
13
    request.
14
              THE COURT: Okay. Well, why don't you do that?
15
              MR. WARNER: Well -- well, because I -- well, --
16
    well, so let me -- let me back up a little bit. OSHA only has
17
    things when there's a problem. OSHA requires certain testing,
18
    nevertheless even when there's not a problem.
19
              THE COURT: Right.
20
              MR. WARNER: OSHA requires testing in factories.
21
    OSHA requires testing in embalming rooms. OSHA requires all
22
    sorts of crazy stuff now and --
23
              THE COURT: Okay.
24
              MR. WARNER: -- and it changed all over the decades.
25
    And -- and I guess I -- I just thought -- I just saw -- and --
```

```
53
                               Colloquy
1
    and I'm -- and please forgive me, guys, I am not trying -- I
2
    just thought a lot of this was implied, that's what -- but --
    but let me be more specific. That's fine. I mean, we'll make
3
4
    it more specific. That's -- we'll -- we'll per --
5
              THE COURT: Either --
6
              MR. WARNER: -- we'll confer.
7
              THE COURT: -- make it more specific --
8
              MR. WARNER: Yeah.
9
              THE COURT: -- and/or --
              MR. WARNER: Yeah.
10
11
              THE COURT: -- brief it more specifically --
12
              MR. WARNER: Okay. Okay.
13
              THE COURT: -- and/or go to -- get a FOIA request
    from OSHA.
14
15
              MR. WARNER: But -- but again but the only --
16
              THE COURT: Send out a FOIA -- send out a FOIA --
17
              MR. WARNER: -- the only problem with that though is
18
    that the -- you know, you only get them when there's a
19
    problem.
              So, maybe in 1997, you know, a vat spilled and they
20
    were --
21
              THE COURT: Well, before we go down that road, be
22
    more specific in this --
23
              MR. WARNER: Okay.
24
              THE COURT: -- particular request. Okay?
25
             MR. WARNER: You got it. Yeah. Thank you.
```

```
54
                               Colloquy
1
              THE COURT: I need you to make a more coherent
2
    connection.
3
              MR. WARNER: Understood, Your Honor. Well, you mean
4
    -- you mean briefing to Your Honor or --
5
              THE COURT: Yes. Well, see if you can work it out.
6
              MR. WARNER: Okay. Okay.
7
              THE COURT: But if not, --
8
              MR. WARNER: Okay.
9
              THE COURT: -- if you can't work it out, I'm --
10
   before I was saying --
11
              MR. WARNER: Okay.
12
              THE COURT: -- simply saying you need to meet and
13
    confer and I know you're going to be successful. On this one,
14
    meet and confer, but if you're not successful right away, send
15
    me a more detailed letter --
16
              MR. WARNER: Understood, Your Honor.
17
              THE COURT: -- as to why this is relevant to your
18
    claims and defense -- your claims in this lawsuit or their
19
    defenses.
20
              MR. WARNER: Absolutely.
21
              THE COURT: Okay. Next?
22
              MR. DE LA GARZA: We have one more area, Your Honor,
23
    but I did hear counsel in that prior discussion make a
24
    reference to EU regulations, you know, Canadian regulations.
25
    Well, we're in the United States. This is in New Jersey.
```

Colloguy 55

certainly want to make sure that we're not required to produce any documents that are outside of the United States.

I've had -- we didn't even know we had an issue about that until I heard all of this discussion of EU and Canada, because it's not in any discussion we've had up to this point.

THE COURT: Mm-hmm.

MR. DE LA GARZA: So, all right. The next area is there are requests for us to provide what we consider to be attorney work product, pure litigation related files --

THE COURT: All litigation files, number 15?

MR. DE LA GARZA: -- relating to other matters. And so the first one though, it's in request number 12. They ask for each and every law which governs any aspect of the chain of distribution of the products the subject of this litigation. So, they want us to -- to make copies of the laws that we think are relevant to the chain of distribution. Our client is not going to have that. That would be something that either they receive from a lawyer -- there are no -- we're -- we're not legal firms, we're chemical manufacturers, and so it's either going to come from a lawyer, which is attorney-client privilege, or it's going to ask us to make that decision of what is that applicable law related to the chain of distribution.

There is no need for this and, frankly, that's just

Colloquy 56

1 all attorney work product. So, that was number 12.

Number 15 asks for litigation files related to other lawsuits since 1990. And that would be attorney work product, as well, and frankly not relevant. This case is not going to be decided based upon how another case went. That's a pure fishing expedition.

And then number 16 asks for documents that refer to complaints about products -- so, number 16. Every document that refers to a complaint concerning the products in litigation. Okay. Well, that's not narrowly constrained to the facts of this case. If, for example, somebody sent us a complaint and said the box was damaged or this gives me the wrong color, it's not the rosy pink that you advertised, it's the red rose and I can't sell that, that's just not cons -- narrowly tailored to the needs of this case.

So, those are -- that's the next category, 12, 15 and 16.

THE COURT: All right. Number -- let's go in reverse order.

MR. WARNER: And may I?

THE COURT: Sure.

MR. WARNER: Okay. Well, again, I thought this was implied. I mean, if they had just simply answered under an objection we're not going to give you complaints about a torn box, that would be perfectly acceptable. But it somebody

57 Colloquy 1 writes back and says, you know, I -- I got a severe skin 2 irritation or, you know, and for all -- you know, look. 3 THE COURT: Let's start this way. 4 MR. WARNER: Mm-hmm. 5 THE COURT: They'll give you all complaints -- and 6 we'll talk about what that means in a minute -- all complaints 7 about cancer or leukemia. 8 MR. WARNER: Fair enough, Your Honor. 9 THE COURT: Now, what do you mean by complaints? 10 MR. WARNER: Well, I --11 THE COURT: Because here's the thing. I don't know 12 -- and I don't know if you've -- I'm sure you do know, 13 actually, the answer to this question -- is how your clients 14 record consumer complaints, whether they record them. I mean, 15 I'm sure they do. How and how voluminous they are. Whether 16 they can be broken down by cancer slash leukemia. And that's 17 one form of complaint, and then the other are litigations. 18 MR. WARNER: Right. I --19 THE COURT: I mean, that you should have a record 20 of. How many times you've been sued by any consumer or 21 anybody where the allegation is that your products cause 22 cancer or leukemia. I know cancer is a little broader, but 23 I'm going to go there. 24 MR. WARNER: I -- I -- and I don't want -- I don't 25 want their work products, Your Honor. I don't want their

```
58
                               Colloquy
1
    memoranda about, you know, how -- you know, how --
2
              THE COURT: No, well, okay, but let's just do one
3
    thing at a time.
4
              MR. WARNER: Okay. Oh, --
5
             MS. WEISSLITZ: Your Honor, I just want to make
6
    clear that we're talking about embalming fluids. These are
7
    not products that are marketed or used by --
8
              THE COURT: No, I know that.
9
              MS. WEISSLITZ: -- everyday consumers.
10
              THE COURT: When I use the word consumer, I mean
11
    somebody who bought your marketing product.
12
              MS. WEISSLITZ: Yeah, and there -- and there's not --
13
              THE COURT: I mean, not marketing product, --
14
              MS. WEISSLITZ: -- and there's not, like, --
15
              THE COURT: -- your embalming product.
16
              MS. WEISSLITZ: -- a hotline where people call up
17
    and say, --
18
              THE COURT: Well, I didn't know if there was or
19
    there wasn't.
20
              MS. WEISSLITZ: Well, I can speak for my client that
21
    there's not.
22
              THE COURT: Okay.
23
             MS. WEISSLITZ: And so we have no problem disclosing
24
    prior litigations. I believe, at least for my client, Mr.
25
    Tandy and Mr. Warner have that information, so --
```

59 Colloquy 1 THE COURT: Okay. MR. WARNER: Well, again, Ms. -- Ms. Weisslitz 2 3 (indiscernible) the Website, the address, I mean, you know, --4 THE COURT: Hmm? What? 5 MR. WARNER: -- they -- they have a -- they have a 6 Website. I believe their Website allows the people to --7 THE COURT: Well, I'm not going to argue that now. 8 I want you to make -- answer the question as to how your 9 client logs in -- if -- whether and how they log in complaints 10 about products. If they have no complaints or no place where 11 they've kept them, then you can answer that. If they've -- if 12 there are -- if --13 MS. WEISSLITZ: Okay. 14 THE COURT: If it turns out to be a burdensomeness 15 issue, then you'll let me know. Otherwise, I think it's 16 relevant. 17 MS. WEISSLITZ: Okay. 18 MR. DE LA GARZA: So, if there's a -- if there is a 19 complaint or -- that is non-litigation, we give the complaint, 20 whatever -- the letter or whatever it is, the email, Website. 21 Or if there's litigation, we give them the complaint, the 22 actual petition complaint and we start there. 23 THE COURT: Right. We start there. You'll review 24 that stuff and then, if you want follow up, we'll -- you could 25 talk to them. And if I have to get involved, I will.

```
60
                               Colloquy
1
              MR. WARNER: Yeah. And -- and look, if -- if
2
    there's something that's -- that -- that was on PACER or
3
    something, then I don't need them to print all that stuff out
    for me. And then, as --
4
5
              THE COURT: Well, you'll just -- you know, just give
6
    me -- you hear that.
7
              MR. WARNER: Yeah. Yeah, I mean, you know, --
8
              THE COURT: You don't need to print every complaint
9
    out, just give them the information.
10
              MR. WARNER: Right. And -- and I --
11
              THE COURT: All right.
12
              MR. WARNER: -- and I -- I -- it --
13
              THE COURT: Complete litigation files. All right.
    I tend -- well, you don't really want complete litigation
14
15
    files.
16
              MR. WARNER: Fair -- fair enough. I --
              THE COURT: And then number 12. Well, this
17
18
    question, Mr. de la Garza edited it when he read it. And I
19
    thought his edit -- his edit made some sense, but that's --
20
    really, it asks for all -- it's too broad and too convoluted
21
    and it asks for too many things in one question.
22
              MR. WARNER: So, I -- I -- I pulled it from -- I --
23
    well, I sort of paraphrased it from the New Jersey form --
24
    what was it? C or A interrogatories that asked violation of
25
    any and all laws, statutes, regulations.
```

```
61
                               Colloquy
1
              THE COURT: Mm-hmm.
2
              MR. WARNER: I don't think it's unfair to say --
3
    well, laws -- well, you know, --
4
              THE COURT: Each and every law --
5
             MR. WARNER: Or -- or -- or what -- what law
6
    are you subject to what -- per regulation. I -- I don't think
7
    that's necessarily unfair to say who are your regulators, who
8
    are your overseers, what do they require of you.
9
              MR. DE LA GARZA: Your Honor, this is not an
10
    interrogatory. This is a request for documents. So, the only
11
    way we're -- we would be able to do that would be, as lawyers,
12
    we would have to go through that exercise, if required to,
13
   print out a law. That just --
14
             MR. WARNER: I -- I would --
15
             MR. DE LA GARZA: And that would be totally attorney
16
    work product, --
17
             MR. WARNER: I would --
18
              MR. DE LA GARZA: -- because we're now having to say
19
    what we think --
20
              THE COURT: Well, I don't want to raise an issue
21
    that you guys haven't argued about yet here, but the bottom
22
    half of the question says "and which was established,
23
   published or promulgated by any professional association,
24
    trade association, industry association, or private group."
25
             MR. WARNER: I -- I think the one above that talks
```

```
62
                               Colloquy
1
    about regulators. I think there's another one that talks
2
    about regulators. I think --
3
              THE COURT: No, the same -- it's in the same
4
    question.
5
              MR. WARNER: Oh, it is? Okay. Well, let's -- I
6
    mean, we're -- we're asking who are your overseers and what do
7
    they require of you and I -- I look at the -- and I -- I -- if
8
    the -- if he wants to make a list instead of printing them
9
    out, that's fine, too. I -- you know, I -- I -- I don't want
10
    -- so, I don't think that hitting print is necessarily
11
    creating attorney work product, but I'm --
12
              THE COURT: I'm not sure why you're asking this
13
    question.
14
              MR. WARNER: Well, I -- again, I -- I -- I --
15
              THE COURT: If I understand what you're asking, you
    should know the answer. Now, I know that's not an appropriate
16
17
    response to a discovery question that you -- that you know it
18
    doesn't mean you can't ask it, but this is not something
19
    that's in dispute.
20
              MR. WARNER: In
21
              THE COURT: Who the -- who regulates them? It's not
22
    like you're going to get a different answer than you would
23
    have expected.
24
              MR. WARNER: Well, so, --
25
              THE COURT: Right?
```

```
63
                               Colloquy
1
              MR. WARNER: Well, not necess --
2
              THE COURT: Am I right about that?
3
              MR. WARNER: I'm not sure, Your Honor, because, you
4
    know, again, the -- these -- I know, for example, Dodge sells
5
    internationally and we -- we -- we'd like to know, you know,
6
    maybe they -- maybe they take different -- maybe they make
7
    their products safer abroad than they do here. And we would
8
    like to know --
9
              THE COURT: They may. They may.
10
              MR. WARNER: -- what regulations they follow -- they
11
    -- they follow. I mean, and I -- I can figure -- I'll -- you
12
    know, we'll -- we'll -- we'll synthesize all that information
13
    once we get it. We'd just like to know, you know, what -- you
14
    know, for example, maybe they belong to the --
15
              THE COURT: Well, let's --
16
              MR. WARNER: -- formaldehyde --
17
              THE COURT: Let's take it one step at a time. What
18
    governmental entity regulates them. You want to know that.
19
              MR. WARNER: Well, --
20
              THE COURT: Even though I think you probably know,
21
    at least for the United States.
22
              MR. WARNER: Right. Sure. And -- and abroad, yeah.
23
              THE COURT: So, you want to know internat --
24
    everywhere they do business, what governmental entity
25
    regulates them. That's number one; right?
```

64 Colloquy 1 MR. WARNER: Yes. Correct. 2 THE COURT: And you then you want to know, aside from governmental entities, whether they are regulated --3 4 let's -- I'm going to just for purposes of my understanding --5 whether they're self-regulated by a professional organization 6 or association. 7 MR. WARNER: Correct. 8 THE COURT: Okay. 9 MR. WARNER: And for all I know, there's something 10 I'm completely unaware of, like the International Organization 11 of Formaldehyde Manufacturers, that says, well, you -- you 12 know, that -- that said in 1988, oh boy, this stuff is really 13 starting to get, you know, looked at closely, we better look 14 into safer ways of --15 THE COURT: Well, it does sound more like an 16 interrogatory than a document demand. 17 MR. WARNER: Well, it does -- it doesn't have to be. 18 He could print it out and I don't think hitting print is --19 THE COURT: What are they going to print out? 20 MR. WARNER: -- is making it attorney work product. 21 THE COURT: What are they -- there is -- I am --22 what are you asking them to print out? Like, it's -- that's 23 an interrogatory question. Who -- to whom do you answer? 24 MR. WARNER: Mm-hmm. Right. Right. 25 THE COURT: To whom are you regulate -- who are you

```
65
                               Colloquy
1
    -- who regulates you.
2
              MR. WARNER: Mm-hmm.
3
              THE COURT: Governmental -- that's an interrogatory
4
    question. I don't think there's a button somebody pushes
5
    somewhere to say here's all our regulators, you have it right
6
    here.
7
              MR. WARNER: Well, but I -- but I think --
8
              THE COURT: Or maybe they do.
9
              MR. WARNER: Well, I -- I -- I think -- fair enough.
10
    I know -- but I think it could be -- I think they could --
11
    they could print out -- and I'm not -- I don't necessarily --
12
    I wouldn't require that. I don't think hitting print is
13
    creating attorney work product, but I -- I -- I think that it
14
    could be --
15
              THE COURT: Well, --
16
              MR. WARNER: -- a document demand and we're saying,
17
    well, what regulations, what -- what -- do you adhere to, what
18
    -- what -- perhaps not maybe legally binding, --
19
              THE COURT: Again, those are --
20
              MR. WARNER: -- but what standards.
21
              THE COURT: Those are deposition -- I mean
22
    interrogatory questions.
23
              I'm not going to make them answer that question.
24
    You -- if you can ask it in an interrogatory or in a
25
    deposition perhaps --
```

66 Colloquy 1 MR. WARNER: Okay. 2 THE COURT: -- when you get a 30(b)(6) witness or 3 something. I mean, I -- I am not telling you that I don't 4 think it would lead -- although this is not the standard 5 anymore -- to admissible evidence. It may -- it may lead to 6 relevant evidence in this case. Maybe. I get it. I 7 understand how I think you would want to use it, depending on 8 what the answer is. But let's just ask it in a more --9 MR. WARNER: And --10 THE COURT: -- in a better way. 11 MR. WARNER: And just may I just say one more thing, 12 Your Honor? That -- that I don't know -- that -- that 13 I've deposed enough of these embalming man -- company 14 manufacturers and we have had CEOs know that when I get there, 15 the answer is going to be "I don't know." Which is why --16 THE COURT: Well, you've got to put -- well, if 17 you're going to do a 30(b)(6) deposition, make sure that you 18 put that as one of your topics. 19 MR. WARNER: Okay. 20 THE COURT: Who it regulates. It's a very simple --21 that's very simple. 22 MR. WARNER: No, no, I -- right and, well, --23 THE COURT: And I think they have probably somebody --24 MR. WARNER: Well -- well, the -- the -- also -- I'm

I didn't mean to interrupt, Your Honor. I was -- I

```
67
                               Colloquy
1
    was just -- I was just going to say, you know, the -- well, I
2
    don't know who -- who in the EU does it, or I don't know who
3
    in Canada does it, I don't know what regulations we're
4
    supposed to follow in Canada, I just -- I just -- I'm just Jim
5
    Jones from Texas, I -- you know, I just make formaldehyde.
6
    You know, that's the answer I get routinely.
7
              THE COURT: Well, you're -- then you haven't given
8
    them a proper 30(b)(6) notice.
9
              MR. WARNER: Okay.
10
              THE COURT: Or, if you have, they're violating the
11
    hell out of it.
12
             MR. WARNER: Okay. Fair enough, Your Honor. Fair
13
    enough. Fair enough.
14
              MR. DE LA GARZA: We do have one remaining demand
15
    and that was document demand number 2. Document demand number
16
    2 asks for documents related to possible alternative
17
    recommended or foreseeable uses of our products. So, --
18
              THE COURT: Oh, yeah.
19
              MR. DE LA GARZA: So, that's like saying what else
20
    could you do with this stuff?
21
              THE COURT: I don't like that one at all.
22
              MR. WARNER: Okay.
23
              THE COURT: That's out.
24
              MR. WARNER: Okav.
25
                            (Extended pause)
```

Case 2:16-cv-05177-ES-JAD Document 97 Filed 08/10/18 Page 68 of 74 PageID: 3004 68 Colloquy 1 THE COURT: Now, we started talking about the fact 2 that your client is sick. And if I didn't make it clear, 3 you've got your six weeks, you've got your four weeks. But 4 how long will you need thereafter -- well, I guess it's you, 5 really -- to get ready to depose his client? 6 MS. WEISSLITZ: After the four weeks? 7 THE COURT: Well, just say from today. I mean, just 8 step back for a minute and think about what you need to get 9 there, because if she's getting sicker, we probably need to do 10 something. 11 MR. DE LA GARZA: So, we have more needs than just 12 how do we dovetail the discovery from this one defendant with 13 this plaintiff over here. 14 THE COURT: Mm-hmm. MR. DE LA GARZA: The plaintiff has not responded to 15 our discovery. I mean, just nothing. There's no letter to 16 17 the Court, --18 THE COURT: Okay. 19 MR. DE LA GARZA: -- there's no discovery response. 20 So, that -- that's another issue that we're going to confer 21 with counsel about, like, when are you going to respond to our

23 THE COURT: Right.

discovery, because --

22

24

25

MR. DE LA GARZA: -- not that sets us back. So, now we've -- but now we have this issue where we may need to take

Colloquy 69

-- we need -- may need to get discovery from the plaintiff and take the deposition of the plaintiff, to the extent that the plaintiff's condition might be worsening.

And, you know, there are other issues involved here. Apparently, she's -- she has another malpractice against somebody for mistreating her for this illness and -- and that -- we really need to get the records to see how do we separate out what you're saying we did with what somebody else did. So, the discovery is now becoming even more paramount, given that we have this deteriorating condition of the plaintiff. That is now going to impact other dates in the scheduling order.

And so, if I may suggest this? I think maybe the best approach is that we need to confer and talk about what is a realistic plan here. We don't know what it is. And I don't believe that counsel here knows what it is, because I don't think counsel knows exactly what her condition is. He's got a report from Mr. Tandy, but we really need to talk to Mr. Tandy, who needs to get a good understanding of what's his client capable of doing and when are they going to get us our discovery.

THE COURT: Well, --

MR. DE LA GARZA: So, what I'd suggest that we do is that we report back to you and tell you whether we think that the scheduling order needs to be changed so that we can get a

70 Colloquy 1 plan that actually works for everybody. MR. WARNER: And -- and I do apologize. We -- we 2 3 have been sifting through -- I -- I think that we've -- we've 4 gone through at least 6,000 pages of medical records already and now we're just getting more and more. And if -- and --5 6 and we -- I mean, in all sincerity, I mean, we are apologetic 7 about that, but we would ask --8 THE COURT: You start to roll them out, I think. 9 MR. WARNER: I'm sorry? 10 THE COURT: Start to roll out those records. You 11 know, you could -- what you've gone through, get in their 12 hands and but tell them that there's more to come. 13 rolling production. 14 MR. WARNER: Okay. THE COURT: That's number one. Number two, you 15 16 agree you should meet and confer --17 MR. WARNER: Absolutely. 18 THE COURT: -- so you can get a handle on how far --19 really what it's going to take for you to get there. And then 20 start to -- find out exactly the -- how your client is doing. 21 MR. WARNER: And -- and Your --22 THE COURT: And then maybe -- it may be that they 23 are going to want to take a de bene esse deposition and you're 24 not going to be ready, I would obviously give you the right to

come back later, assuming that's a viable right, to do a

```
71
                               Colloquy
1
    discovery deposition or to do it at the same time, but to
2
    continue it later after all the -- that -- that may or may not
3
    help us. I am just -- you know what? You guys meet and
4
    confer.
5
              MR. WARNER: We -- we will need the four
6
    weeks, though, to complete our -- at least our initial roll
7
    out there, Your Honor.
8
              THE COURT: You should meet and confer ASAP about
9
    this whole schedule. Okay?
10
              MR. WARNER: Okay.
              THE COURT: I'm here when you're ready.
11
12
              MR. WARNER: Okay.
13
              MR. DE LA GARZA: Okay.
14
              MS. WEISSLITZ: Okay.
15
              THE COURT: All right?
16
              MR. DINO: May I ask a question?
17
              THE COURT: Mm-hmm.
18
              MR. DINO: Counsel had --
19
              THE COURT: No. Go ahead.
20
              MR. DINO: Counsel referred to several times about
21
    regulation and such in the EU and Canada. I was just
22
    wondering the Court's position on whether -- how it feels
23
    about defendants' (indiscernible) information.
24
              THE COURT: I really don't like to do what I am
25
    about to do, but I am not going to tell you, because I don't
```

72 Colloquy 1 know yet, because I think counsel again mentioned this is the 2 first time he's hearing about it and it hasn't been briefed. 3 Off the top of my head, I see pros and cons. I 4 don't know -- I think, if you can't work that out, I think he 5 has to put it in front of me pretty quickly. 6 MR. DINO: That's fine. I just wanted to lodge my 7 objection so that there was no argument that it was made. 8 MR. WARNER: Your Honor, can we just at least be 9 rest assured that we -- we have four weeks to complete our 10 initial roll out of --11 THE COURT: Yeah. Yeah. 12 MR. WARNER: Thank you. Thank you. 13 THE COURT: I -- yeah. I -- I said that. You have 14 the four weeks, --15 MR. WARNER: Okay. 16 THE COURT: -- and when you say complete it, I just 17 wanted you to get it started. 18 MR. WARNER: Yeah. 19 THE COURT: You know, and because the way I 20 understood it, --21 MR. WARNER: Well, --22 THE COURT: -- you were holding everything and then 23 you were going to produce it. I think you should start 24 getting information in their hands. 25 MR. WARNER: No, no, and -- and absolutely, Your

```
73
                               Colloquy
    Honor. I -- and I -- I -- it just -- regrettably, because
1
2
    there's so much that needs to be -- well, yeah, well -- well,
3
    I don't need --
4
              THE COURT: Well, I -- I --
5
              MR. WARNER: -- we -- we don't need to --
6
              THE COURT: You don't need to apologize any more.
7
    You put that on the record. I got it.
8
              MR. WARNER: Okay.
9
              THE COURT: Just start getting it out, to the extent
10
    you can.
11
              MR. WARNER: Uh-huh.
12
              THE COURT: Meet and confer to talk about a whole
13
    schedule and you'll get your stuff done as soon as you can.
14
              MS. WEISSLITZ: Yes. Yes. Very good.
15
              THE COURT: Anything else?
16
              MR. DE LA GARZA: No, Your Honor.
17
              MR. DINO: No, Your Honor.
18
              THE COURT: Okay.
19
              MR. WARNER: I --
20
              THE COURT: Anything else?
21
              MR. WARNER: No, Your Honor.
22
              THE COURT: Okay. Thank you.
23
              MR. WARNER: Thank you, Your Honor.
24
             MS. WEISSLITZ: Thank you.
25
             MR. DE LA GARZA: Thank you, Your Honor.
```